Dianthus Therapeutics, Inc.
DNTH
Rankning i aktier
#3821
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Aktiekurs
$77.80
Senast synkroniserad: 2026-10-21
Marknadsvärde
$4.35B
Förändring (1 dag)
-1.21%
Förändring (1 år)
132.59%
Land
US
Handel Dianthus Therapeutics, Inc. (DNTH)
Kategori
Healthcare
Aktiekurshistorik för Dianthus Therapeutics, Inc. (DNTH)
Högsta slutkurs: $80.75 den 2026-10-01
Lägsta slutkurs: $225.69 den 2018-06-01
Lägsta slutkurs: $225.69 den 2018-06-01
Aktiekurshistorik för Dianthus Therapeutics, Inc. från 2018 till 2026
Årlig aktiekursutveckling
| År | Prestanda |
|---|---|
| 2026 (TTM) | 74.40% |
| 2025 | 79.27% |
| 2024 | 158.65% |
| 2023 | -30.65% |
| 2022 | -83.63% |
| 2021 | -32.46% |
| 2020 | -46.40% |
| 2019 | 100.40% |
| 2018 | 0.00% |
Aktiekurs för liknande företag eller konkurrenter
| Företag | Aktiekurs | Förändring 1år% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.10 | -4.29% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
